Mark Spellman, Alpine Funds Co-Portfolio Manager, explains his views on finding yield in large-cap stocks over mid-caps and gives his picks. » Read More
Up to 1 in 4 primary care doctors say they aren't well prepared to manage care for patients with multiple chronic conditions.
Meanwhile, U.S. stock futures were higher this morning, after the Dow surged 369 points, after Friday's solid jobs report and as ECB President Mario Draghi reassured markets.
The national conversation on drug prices is getting louder, and patients increasingly want a voice in that discussion.
Jim Cramer has declared the U.S. the winner of the trade war on China. So what companies will do best in China?
Paul Meeks, director of institutional investing at Saturna Capital, is scooping up shares of a recently beaten-down technology name.
Louis Navellier, whose "Squawk Box" model portfolio is up 20 percent this year, believes Mohawk Industries will beat earnings.
Philidor, a pharmacy facing backlash from accusations about Valeant Pharmaceuticals' business model, announced it would close.
Some of the names on the move ahead of the open.
On today's final trading day of October, stocks are on track for their best month in four years and a fifth straight winning week.
Valeant said it is terminating all ties with Philidor due to allegations relating to the specialty pharmacy distributor's business practices.
Shares of Valeant plunged as some benefits managers began cutting off business with a pharmacy associated with Valeant.
Walgreens' acquisition of Rite Aid would combine two of the largest U.S. drugstore chains.
This is all about cost savings, driven by Affordable Care Act.
The deal, which could be announced Wednesday, would combine the second-and-third largest U.S. drugstore chains, according to reports.
Expectations are low that the Fed will provide any new policy insight next week, and focus should stay on economic reports and a flood of earnings.
The market for influenza vaccines globally is estimated to be about $4 billion, and growing.
The "Halftime Report" traders give their top trades of the show.
The nation's biggest pharmacy benefits manager has decided to cover two new drugs that lower artery-clogging cholesterol.
Jim Cramer gives his opinion at rapid speed to caller stocks, including this health care play with a scary chart that is screaming to be bought.
Wal-Mart on Tuesday announced a series of initiatives to beef up its health and wellness offerings.